Stay updated on Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.

Latest updates to the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange Detected- Added a government funding notice about potential service disruptions and where to check status, plus a link to cc.nih.gov and opm.gov. - Updated version from v3.0.2 to v3.2.0.SummaryDifference12%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; aside from that, no changes to core content, pricing, stock, or time slot availability.SummaryDifference0.7%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.7%
- Check48 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.SummaryDifference14%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check71 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
Stay in the know with updates to Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.